{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05376878",
            "orgStudyIdInfo": {
                "id": "21050"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2022-03220",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "21050",
                    "type": "OTHER",
                    "domain": "City of Hope Medical Center"
                },
                {
                    "id": "P30CA033572",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P30CA033572"
                }
            ],
            "organization": {
                "fullName": "City of Hope Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis",
            "officialTitle": "Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "an-investigational-scan-dota-trastuzumab-pet-mri-in-imaging-patients-with-breast-cancer-with-brain-metastasis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2022-12-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-25",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-25",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-03",
            "studyFirstSubmitQcDate": "2022-05-11",
            "studyFirstPostDateStruct": {
                "date": "2022-05-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "City of Hope Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \\[PET\\]/magnetic resonance imaging \\[MRI\\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. Evaluate the feasibility of 64Cu-DOTA-trastuzumab PET imaging in patients with HER2+ breast cancer metastatic to the brain.\n\nII. Evaluate if HER2+ breast cancer patients with brain metastasis who are responders to fam-trastuzumab deruxtecan have higher maximum standardized uptake value (SUVmax) (minimum over all lesions in the brain) than non-responders.\n\nSECONDARY OBJECTIVE:\n\nI. Evaluate if the minimum SUVmax of all quantifiable lesions in a given patient is associated with time to progression in the brain.\n\nOUTLINE:\n\nPatients receive trastuzumab intravenously (IV) over 15 minutes on day 0. Patients then receive 64Cu-DOTA-trastuzumab IV and then undergo PET/MRI scan on day 1. Patients undergo repeat brain MRI every 6 weeks for 24 weeks and then every 9 weeks until disease progression. Patients then receive trastuzumab deruxtecan IV every 21 days in the absence of disease progression or unacceptable toxicity."
        },
        "conditionsModule": {
            "conditions": [
                "Anatomic Stage IV Breast Cancer AJCC v8",
                "Metastatic Breast Carcinoma",
                "Metastatic Malignant Neoplasm in the Brain"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive trastuzumab IV over 15 minutes on day 0. Patients then receive 64Cu-DOTA-trastuzumab IV and then undergo PET/MRI scan on day 1. Patients undergo repeat brain MRI every 6 weeks for 24 weeks and then every 9 weeks until disease progression. Patients then receive trastuzumab deruxtecan IV every 21 days in the absence of disease progression or unacceptable toxicity.",
                    "interventionNames": [
                        "Other: Copper Cu 64-DOTA-Trastuzumab",
                        "Procedure: Magnetic Resonance Imaging",
                        "Device: Positron Emission Tomography",
                        "Biological: Trastuzumab",
                        "Biological: Trastuzumab Deruxtecan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Copper Cu 64-DOTA-Trastuzumab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)"
                    ],
                    "otherNames": [
                        "64Cu-DOTA-Trastuzumab"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Magnetic Resonance Imaging",
                    "description": "Undergo PET/MRI",
                    "armGroupLabels": [
                        "Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)"
                    ],
                    "otherNames": [
                        "Magnetic Resonance Imaging Scan",
                        "Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance",
                        "MR",
                        "MR Imaging",
                        "MRI",
                        "MRI Scan",
                        "NMR Imaging",
                        "NMRI",
                        "Nuclear Magnetic Resonance Imaging"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Positron Emission Tomography",
                    "description": "Undergo PET/MRI",
                    "armGroupLabels": [
                        "Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)"
                    ],
                    "otherNames": [
                        "Medical Imaging, Positron Emission Tomography",
                        "PET",
                        "PET Scan",
                        "Positron Emission Tomography Scan",
                        "Positron-Emission Tomography",
                        "proton magnetic resonance spectroscopic imaging"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Trastuzumab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)"
                    ],
                    "otherNames": [
                        "ABP 980",
                        "ALT02",
                        "Anti-c-ERB-2",
                        "Anti-c-erbB2 Monoclonal Antibody",
                        "Anti-ERB-2",
                        "Anti-erbB-2",
                        "Anti-erbB2 Monoclonal Antibody",
                        "Anti-HER2/c-erbB2 Monoclonal Antibody",
                        "Anti-p185-HER2",
                        "c-erb-2 Monoclonal Antibody",
                        "HER2 Monoclonal Antibody",
                        "Herceptin",
                        "Herceptin Biosimilar PF-05280014",
                        "Herceptin Trastuzumab Biosimilar PF-05280014",
                        "Herzuma",
                        "Kanjinti",
                        "MoAb HER2",
                        "Monoclonal Antibody c-erb-2",
                        "Monoclonal Antibody HER2",
                        "Ogivri",
                        "Ontruzant",
                        "PF-05280014",
                        "rhuMAb HER2",
                        "RO0452317",
                        "SB3",
                        "Trastuzumab Biosimilar ABP 980",
                        "Trastuzumab Biosimilar ALT02",
                        "trastuzumab biosimilar EG12014",
                        "Trastuzumab Biosimilar HLX02",
                        "Trastuzumab Biosimilar PF-05280014",
                        "Trastuzumab Biosimilar SB3",
                        "Trastuzumab Biosimilar SIBP-01",
                        "Trastuzumab-anns",
                        "Trastuzumab-dkst",
                        "Trastuzumab-dttb",
                        "Trastuzumab-pkrb",
                        "Trastuzumab-qyyp",
                        "Trazimera"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Trastuzumab Deruxtecan",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Treatment ( 64Cu-DOTA-trastuzumab PET/MRI)"
                    ],
                    "otherNames": [
                        "DS-8201",
                        "DS-8201a",
                        "Enhertu",
                        "Fam-trastuzumab Deruxtecan-nxki",
                        "WHO 10516"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent of patients with quantifiable 64Cu-DOTA-trastuzumab PET uptake",
                    "description": "Percentage of patient with quantifiable 64Cu-DOTA-trastuzumab PET imaging (maximum standardized uptake value\\[SUVmax\\]) uptake in brain lesions.",
                    "timeFrame": "Until disease progression or death, up to 5 years."
                },
                {
                    "measure": "Comparison of average min SUVmax values in responders versus non-responders.",
                    "description": "Comparison evaluated using a non-parametric test. The lowest SUVmax (minimum SUVmax) across the lesions will be the primary metric used. Response assessment for CNS disease is determined by MRI of the brain using Response Assessment in Neuro-Oncology (RANO) criteria.",
                    "timeFrame": "Until disease progression or death, up to 5 years."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression-free Survival",
                    "description": "Estimated using the product-limit method of Kaplan and Meier. Progression defined by any of the following: \\> 25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration.",
                    "timeFrame": "From start of treatment until progression or death from any cause, up to 5 years."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Documented informed consent of the participant and/or legally authorized representative\n* Women with documented metastatic HER2 positive breast cancer (American Society of Clinical Oncology \\[ASCO\\] College of American Pathologist \\[CAP\\] guidelines) who have brain metastases\n* Age \\> 18 years\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Patients with leptomeningeal disease will be considered eligible\n* Planned therapy with fam-trastuzumab deruxtecan\n* Left ventricular ejection fraction (LVEF) \\> 50%\n* Absolute neutrophil count (ANC) \\> 1.5 x 10\\^9/L\n* Platelets \\> 100 x 10\\^9/L\n* Hemoglobin \\> 9 g/dL\n* Total (T.) bilirubin \\< 3 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 5 x ULN\n* Creatinine clearance \\> 30 ml/min (by Cockcroft-Gault formula)\n* Activated partial thromboplastin time (aPTT) \\< 1.5 x ULN\n* Prior therapy for central nervous system (CNS) disease is allowed, but at least 1 lesion \\> 1.5 cm is evident on MRI\n\nExclusion Criteria:\n\n* Need for immediate local intervention for brain metastases\n* Noninfectious interstitial lung disease or pneumonitis requiring glucocorticoids\n* Clinically significant corneal disease\n* Myocardial infarction \\< 6 months before, congestive heart failure (CHF), unstable angina, or serious cardiac arrhythmia",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Joanne E Mortimer",
                    "affiliation": "City of Hope Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope Medical Center",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joanne E. Mortimer",
                            "role": "CONTACT",
                            "phone": "626-256-4673",
                            "phoneExt": "81218",
                            "email": "jmortimer@coh.org"
                        },
                        {
                            "name": "Joanne E. Mortimer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                },
                {
                    "id": "D000002166",
                    "term": "Camptothecin"
                },
                {
                    "id": "C000712788",
                    "term": "Trastuzumab biosimilar HLX02"
                },
                {
                    "id": "D000000906",
                    "term": "Antibodies"
                },
                {
                    "id": "D000007136",
                    "term": "Immunoglobulins"
                },
                {
                    "id": "D000000911",
                    "term": "Antibodies, Monoclonal"
                },
                {
                    "id": "C000614160",
                    "term": "Trastuzumab deruxtecan"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000059004",
                    "term": "Topoisomerase I Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "asFound": "Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233243",
                    "name": "Trastuzumab deruxtecan",
                    "asFound": "Tilt",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6523",
                    "name": "Copper",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "asFound": "Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "asFound": "Double-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M348931",
                    "name": "Trastuzumab biosimilar HLX02",
                    "asFound": "Erlotinib 150 mg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "asFound": "Double-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5426",
                    "name": "Camptothecin",
                    "asFound": "Progressive Muscle Relaxation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "asFound": "Progressive Muscle Relaxation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M29349",
                    "name": "Topoisomerase I Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T338",
                    "name": "Copper Supplement",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Mi",
                    "name": "Mineral"
                }
            ]
        }
    },
    "hasResults": false
}